Waldron Private Wealth LLC Sells 5,563 Shares of Pfizer Inc. (NYSE:PFE)

Waldron Private Wealth LLC reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 8.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 56,836 shares of the biopharmaceutical company’s stock after selling 5,563 shares during the quarter. Waldron Private Wealth LLC’s holdings in Pfizer were worth $1,508,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of PFE. Swiss National Bank boosted its stake in Pfizer by 0.6% in the third quarter. Swiss National Bank now owns 16,819,712 shares of the biopharmaceutical company’s stock valued at $486,762,000 after acquiring an additional 100,900 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Pfizer by 11.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company’s stock worth $3,766,366,000 after purchasing an additional 12,864,343 shares during the last quarter. Empowered Funds LLC grew its stake in shares of Pfizer by 80.9% during the third quarter. Empowered Funds LLC now owns 508,256 shares of the biopharmaceutical company’s stock worth $14,709,000 after purchasing an additional 227,349 shares during the period. Addison Advisors LLC grew its holdings in Pfizer by 394.2% during the third quarter. Addison Advisors LLC now owns 52,238 shares of the biopharmaceutical company’s stock valued at $1,512,000 after purchasing an additional 41,668 shares during the period. Finally, KBC Group NV increased its stake in Pfizer by 26.0% in the third quarter. KBC Group NV now owns 3,105,433 shares of the biopharmaceutical company’s stock valued at $89,872,000 after purchasing an additional 639,985 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Down 1.5 %

NYSE PFE opened at $26.51 on Friday. The company has a market cap of $150.20 billion, a PE ratio of 35.82, a PEG ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The stock has a 50 day moving average of $26.25 and a 200-day moving average of $27.89. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. During the same period in the prior year, the firm earned ($0.17) EPS. Pfizer’s quarterly revenue was up 31.2% compared to the same quarter last year. On average, equities research analysts anticipate that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a $0.43 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 annualized dividend and a yield of 6.49%. Pfizer’s dividend payout ratio is currently 232.44%.

Analyst Ratings Changes

Several brokerages recently commented on PFE. Sanford C. Bernstein initiated coverage on Pfizer in a research note on Thursday, October 17th. They set a “market perform” rating and a $32.00 price objective on the stock. Wolfe Research initiated coverage on Pfizer in a research note on Friday, November 15th. They set an “underperform” rating and a $25.00 target price for the company. StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Wednesday, October 23rd. Finally, Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.